Skip to content
10-Q

Quarterly Report

Pulse Biosciences, Inc. PLSE

0001437749-26-016897

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 69.21M sh
Capex Q1 2026 · Mar 31, 2026 $33K
Capex Q1 2026 · Mar 31, 2025 $45K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$14.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.52M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $68.32M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $80.74M
Stockholders Equity Q1 2026 · Mar 31, 2026 $66.3M
Stockholders Equity Q1 2026 · Dec 31, 2025 $80.66M
Stockholders Equity Q1 2026 · Mar 31, 2025 $118.45M
Stockholders Equity Q1 2026 · Dec 31, 2024 $114.86M
Current Liabilities Q1 2026 · Mar 31, 2026 $9.8M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.92M
Total Liabilities Q1 2026 · Mar 31, 2026 $15.32M
Total Liabilities Q1 2026 · Dec 31, 2025 $13.88M
Current Assets Q1 2026 · Mar 31, 2026 $71.13M
Current Assets Q1 2026 · Dec 31, 2025 $83.42M
Total Assets Q1 2026 · Mar 31, 2026 $81.62M
Total Assets Q1 2026 · Dec 31, 2025 $94.54M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.27
Eps Basic Q1 2026 · Mar 31, 2025 −$0.25
Sga Expense Q1 2026 · Mar 31, 2026 $6.59M
Sga Expense Q1 2026 · Mar 31, 2025 $7.73M
Rd Expense Q1 2026 · Mar 31, 2026 $12.59M
Rd Expense Q1 2026 · Mar 31, 2025 $10.31M
Net Income Q1 2026 · Mar 31, 2026 −$18.58M
Net Income Q1 2026 · Mar 31, 2025 −$16.8M
Operating Income Q1 2026 · Mar 31, 2026 −$19.15M
Operating Income Q1 2026 · Mar 31, 2025 −$18.04M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $370K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $0
Revenue Q1 2026 · Mar 31, 2026 $401K
Revenue Q1 2026 · Mar 31, 2025 $0